• Island Pharmaceuticals files IND application for Dengue fever drug
  • IMEXHS nabs 3-year Mexican contract for radiology software 
  • COSOL wins $8.2 million Aussie Department of Defence contract


Antiviral drug development company Island Pharmaceuticals (ASX:ILA) has filed its Investigational New Drug (IND) application for the ISLA-101 Phase 2a PEACH clinical trial with the United States Food and Drug Administration (FDA).

It’s a big milestone for the company, because an IND application is essentially a request for approval from the FDA to administer an investigational drug or biological product to humans.

ISLA-101 is a well-known drug candidate that is being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases and the PEACH study will investigate the Prophylactic Examination of an Antiviral in a Dengue Challenge model.

Dengue fever is a viral infection transmitted to humans through the bite of infected mosquitoes, with severe cases leading to serious illness and death, with the World Health Organisation (WHO) estimating there are now 390 million dengue virus infections per year. 

“This submission follows the recent Institutional Review Board (IRB) approval for our Phase 2a PEACH clinical trial in dengue fever, and IND clearance will be the final, critical step before we can begin the trial,” Island CEO and MD Dr David Foster said.

Presuming the IND is cleared by the US FDA in around 30 days, Island’s PEACH clinical trial could begin screening and enrolling subjects in January 2023. 


ILA share price today:


Other health stocks with news today:


The medical imaging software and radiology company has won a 3-year contract to provide enterprise imaging solutions to Mexico’s Social Security Institute (IMSS). The deal will contribute between US$230,000 and $300,000 (approximately AUD$340,000 to $440,000) in Annual Recurring Revenue (ARR), IME says. 

“This appointment of IMEXHS Enterprise software to one of the largest Social Security programs in the world, with 6 out of every 10 Mexicans a part of the IMSS, is a validation of our progress,” co-founder and CEO Dr Germán Arango said.

“Our technology is not only user-friendly and intuitive, but will also provide the IMSS with significant operational efficiencies, reduced costs and considerably improve patient care.” 

Under the agreement, IMEXHS’s local partner Ingenieria para el Cuidado de la Salud, S.A. will implement both AQUILA (IMEXHS’s radiology platform) and ALULA (IMEXHS’s pathology platform). 

The software is expected to go live in the first quarter of 2023.



Medlab has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (SEC) for proposed US public offering of new securities for dual listing of the company. 

Medlab has applied to list its securities on Nasdaq Capital Market under the ticker symbol MDLB. 

The company’s ordinary shares are listed, and upon the completion of the Offering, will continue to trade on the ASX.


IME and MDC share prices today:


ASX Tech stocks with notable news:


The asset management platform has signed a new contract with a value of $8.2 million to deliver services to the Australian Department of Defence.

The contract will see COSOL work in partnership with IBM to deliver services under the Defence Enterprise Resource Planning Program (ERP Program). 

“At the heart of this contract win is our proprietary software RPConnect which facilitates the safe, efficient migration of data from legacy systems to new platforms primed to achieve maximum efficiency and savings from the management of large, asset intensive networks,” CEO Scott McGowan says.

This project work for Defence is expected to be completed in November 2023 and will “contribute positively to COSOL’s financial performance in FY23” the company says.



The company has signed a definitive agreement to acquire 100% of SalesDirector.ai, a leading revenue intelligence and data platform, for $1.2m.

The SalesDirector.ai technology links people, activity and engagement across the buyer’s journey to derive insights, including opportunity risk and relationship strength, and then makes intelligent recommendations. 

“By capturing all sales, marketing, and customer success activity the technology drives actionable revenue insights required to make the right business decisions,” the company said.

“Combining SalesDirector.ai technology with Bigtincan’s existing content, engagement and relationship analytics enhances Bigtincan’s AI-powered insights capabilities to drive guided selling and improve forecasting accuracy.”

Revenue intelligence – a core part of Sales Analytics – is predicted to be a US$4B market by 2025, however, the SalesDirector.ai revenue in FY23 is not expected to be material.



The employee well-being company has signed a three-year US$5.1 million enterprise contract with Marsh McLennan, a global professional services firm, representing Contracted Annual Recurring Revenue (CARR) of $1.7 million. 

Marsh McLennan is slated to launch Limeade to its global workforce in March 2023. 



The wagering platform has responded to media speculation around a potential sale of its Australian business – stating that it is “currently in discussions with NTD Pty Limited (NTD), owners and operators of Australian wagering operator Betr, regarding a potential transaction involving the sale of its Australian trading business and notes that any potential transaction will be assessed in the context of PointsBet’s global strategy and opportunities.”

The company noted however that the discussions are incomplete and preliminary in nature and there’s no certainty it will result in any binding transaction.

“PointsBet advises that as part of its ordinary course of business it routinely explores options to maximise value for shareholders including evaluating proposals from third parties that are received from time to time,” the company said.


COL, BTH, LME and PBH share prices today:


At Stockhead we tell it like it is. While Medlab Clinical is a Stockhead advertiser, it did not sponsor this article.